China Approves Tzield to Delay Type 1 Diabetes Onset in Children and Adults

The Chinese National Medical Products Administration (NMPA) has approved Tzield (teplizumab) as a disease-modifying therapy for type 1 diabetes. The approval applies to children and adults aged 8 and older who have stage 2 type 1 diabetes—a phase where the immune system is actively attacking insulin-producing beta cells, but patients have not yet developed clinical diabetes requiring insulin treatment.

This marks the first approved therapy in China specifically designed to delay the progression of type 1 diabetes. The review process moved quickly, receiving priority status due to recognition of the drug's innovative approach and potential benefit, especially for younger patients.

The approval is based on results from the TN-10 phase 2 clinical trial. In this study, patients receiving Tzield experienced a significant delay in developing stage 3 type 1 diabetes—the point at which clinical symptoms appear and insulin treatment becomes necessary.

Patients who received Tzield had a median delay of 48.4 months before progressing to stage 3 disease, compared to 24.4 months in those who received placebo. This means the treatment extended the period before diabetes onset by approximately two years in the median patient.

Tzield is administered as a single, consecutive 14-day course given once daily. The treatment's mechanism focuses on preserving beta-cell function—slowing the immune system's destruction of the cells that produce insulin.

By extending the time before stage 3 type 1 diabetes develops, Tzield potentially gives patients a longer period without the need for daily insulin injections and intensive diabetes management. This approach represents a shift toward disease-modifying therapy rather than managing symptoms after diabetes is fully established.

This is the first disease-modifying therapy for type 1 diabetes approved in China. It aligns with recent expert consensus guidelines in China that emphasize the importance of protecting beta-cell function in patients with stage 2 type 1 diabetes.

For families in China facing a diagnosis of stage 2 type 1 diabetes, this approval provides a new treatment option aimed at delaying disease progression. Patients and families should discuss with their healthcare team whether they meet criteria for stage 2 diagnosis and whether this therapy might be appropriate for their individual circumstances.

Origin: biopharmaapac.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.